IOVA Abuzz, SUPN Study Flops, IMV Plunges Despite Positive Ovarian Cancer Data

(RTTNews) - Today's Daily Dose brings you news about IMV's ovarian cancer trial results, reports of Iovance considering a possible sale, Nemaura's head -to-head study with a major Glucose Monitoring System, and disappointing trial results of Vanda and Supernus.

Read ona?¦

IMV Inc. (IMV) reported updated results from DeCidE1, an ongoing phase II study of its lead candidate, DPX-Survivac, in patients with advanced recurrent ovarian cancer.

According to the updated results, 79% of evaluable patients achieved disease control, 53% experienced a decrease in the size of the tumor while 37% achieved durable clinical benefit lasting more than 6 months.

Armed with the promising data, the Company plans to request the FDA for a Type B meeting to finalize the design of a pivotal phase IIb study that could support the accelerated approval pathway.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2020    »